MCL1 and plasma cell myeloma: Type I IFNs also upregulate the survival factors MCL1, the apoptosis regulator BCL2 family member (MCL1) and interferon alpha inducible protein 6 (IFI6, best known as G1P3) in myeloma and estrogen-receptor positive breast cancer, respectively, thus promoting poor patient outcome [214,215].